论文部分内容阅读
我厂的前身是蛋品厂,通过改建,于1971年转为生产四环素、盐酸四环素、红霉素、麦迪霉素、洁霉素、注射葡萄糖原料药和80多种针片剂,以及药用辅料等制药厂。转产十几年来,规模日益扩大,生产发展较快。但是,经济效益却一直上不去。特别是近5年,由于医药市场竞争激烈,产品连续大幅度降价,年实现利润始终徘徊在200万元到300万元之间。去年通过实行厂长负责制等一系列改革,加快了企业由生产型向经营型、开拓型的转变,在药品大幅度降价的情况下,工业总产值比1983年增长53%,实现利润增长23.5%;劳动生产率提高41%;可比产品
The predecessor of our factory was an egg factory, which was transformed into tetracycline, tetracycline hydrochloride, erythromycin, midamycin, lincomycin, injectable glucose raw materials and more than 80 kinds of needle tablets, and pharmaceutical excipients. And other pharmaceutical factories. In the past ten years since the transfer of production, the scale has been expanding and the production has developed rapidly. However, economic efficiency has not been able to keep up. Especially in the recent five years, due to the fierce competition in the pharmaceutical market, the products have continuously reduced prices substantially, and the annual profits have always hovered between 2 million and 3 million yuan. Last year through a series of reforms such as the implementation of the director responsibility system, the company accelerated its transformation from a production model to a management model and a pioneering model. Under a situation in which medicines were substantially reduced in price, the total industrial output value increased by 53% compared with 1983 and the profit growth was 23.5. %; labor productivity increased by 41%; comparable products